Relay Therapeutics, Inc. RLAY
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- +90.54%
- 1 year
- +152.66%
5D -1.76 (-9.96%)
- Market cap
- 3.56B
- Revenue (ttm)
- 10.35M
- EPS (ttm)
- -1.50
- Shares out
- 220.96M
- Forward P/E
- -10.26
- YTD return
- +90.54%
- 1-year return
- +152.66%
- 50-day average
- 18.18
- 200-day average
- 15.70
- Enterprise value
- 2.69B
- Volume
- 3.98M
- Avg volume
- 2.92M
- Open
- 15.59
- Previous close
- 15.91
- Day's range
- 15.17 – 16.32
- 52-week range
- 6.28 – 21.27
- Beta
- 1.74
- Analysts
- Strong Buy
- Price target
- 28.25 (+75.2%)
- Earnings date
- Feb 25, 2027
Key statistics
- Price / sales
- 344.14
- Price / book
- 4.32
- Free cash flow
- -117.45M
- Total cash
- 848.64M
- Total debt
- 27.03M
- Return on equity
- -41.16%
- Short % of float
- 22.96%
Fundamental scorecard
6 of 25 checks passed on RLAY’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 25.00
- Target (mean)
- 28.25
- Target (high)
- 32.00
- Strong buy3
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.3541.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.38 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.39676 | -0.37 | +0.03 | +6.74% |
| Aug 6, 2026 | Jun 30, 2026 | -0.39107 | -0.41 | -0.02 | -4.84% |
| May 5, 2026 | Mar 31, 2026 | -0.35 | -0.41 | -0.06 | -17.14% |
| Feb 26, 2026 | Dec 31, 2025 | -0.38 | -0.32 | +0.06 | +15.79% |
| Nov 6, 2025 | Sep 30, 2025 | -0.39 | -0.43 | -0.04 | -10.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Jones Trading | main | Buy | Buy |
| Aug 20, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 10, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Aug 7, 2026 | Barclays | main | Overweight | Overweight |
| Jul 21, 2026 | Goldman Sachs | main | Buy | Buy |
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- relaytx.com
News
Your note
Sign in to keep a note on RLAY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS BRIAN R | Officer | Sale | Jul 28, 2025 | 371,472 |
| BERGSTROM DONALD A. | Officer | Sale | Sep 7, 2026 | 399,130 |
| CATINAZZO THOMAS J | Chief Financial Officer | Sale | Oct 5, 2026 | 105,134 |
| PATEL SANJIV NARATANBHAI | Chief Executive Officer | Sale | Oct 6, 2026 | 1,358,200 |
| RAHMER PETER J | Officer | Sale | Aug 25, 2026 | 223,657 |
| SVF PAULING CAYMAN LTD | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 24, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.97% | 24,239,485 | 390.74M | Sep 29, 2026 |
| SB Investment Advisers (UK) LTD | 9.91% | 21,904,963 | 353.11M | Sep 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 8.09% | 17,868,157 | 288.03M | Sep 29, 2026 |
| Blackrock Inc. | 7.56% | 16,700,112 | 269.21M | Sep 29, 2026 |
| Casdin Capital, LLC | 7.26% | 16,035,240 | 258.49M | Sep 29, 2026 |
| Perceptive Advisors Llc | 5.76% | 12,730,336 | 205.21M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.08% | 6,800,083 | 109.62M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.20% | 4,863,236 | 78.40M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.14% | 4,719,924 | 76.09M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.18% | 2,617,297 | 42.19M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.94% | 2,080,000 | 33.53M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.88% | 1,943,788 | 31.33M | Jun 29, 2026 |
